Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

doi:10.1186/s13046-020-01805-6

	Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
	Ma,Liying 1,2,3; Bian,Xing 1,2,3; Lin,Wenchu 1,2
刊名	Journal of Experimental & Clinical Cancer Research
	2021-01-05
卷号	40
DOI	10.1186/s13046-020-01805-6
通讯作者	Lin,Wenchu(wenchu@hmfl.ac.cn)
英文摘要	An amendment to this paper has been published and can be accessed via the original article.
语种	英语
出版者	BioMed Central
WOS记录号	BMC:10.1186/S13046-020-01805-6
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/125701]
专题	中国科学院合肥物质科学研究院
通讯作者	Lin,Wenchu
作者单位	1.Chinese Academy of Sciences; Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science 2.Chinese Academy of Sciences; High Magnetic Field Laboratory 3.University of Science and Technology of China
推荐引用方式 GB/T 7714	Ma,Liying,Bian,Xing,Lin,Wenchu. Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer[J]. Journal of Experimental & Clinical Cancer Research,2021,40.
APA	Ma,Liying,Bian,Xing,&Lin,Wenchu.(2021).Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.Journal of Experimental & Clinical Cancer Research,40.
MLA	Ma,Liying,et al."Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer".Journal of Experimental & Clinical Cancer Research 40(2021).